Valuation: IMPACT Therapeutics, Inc

Market Cap 2.72B 3.19B 406M 354M 335M 304M 568M 38.89B 571M 3.99B 1.54B 19.77B 1.53B 1.49B 63.27B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.91B 2.23B 284M 248M 234M 213M 398M 27.23B 400M 2.79B 1.08B 13.84B 1.07B 1.04B 44.31B EV / Sales 2026 *
7.2x
EV / Sales 2027 * 2.73x
Free-Float
53.09%
Yield 2026 *
-
Yield 2027 * -
1 day+0.09%
1 week-10.05%
Current month-21.99%
1 month-12.15%
3 months-69.92%
1 week 10.7
Extreme 10.7
15.87
1 month 10.7
Extreme 10.7
17.1
Current year 10.31
Extreme 10.31
47.98
1 year 10.31
Extreme 10.31
47.98
3 years 10.31
Extreme 10.31
47.98
5 years 10.31
Extreme 10.31
47.98
10 years 10.31
Extreme 10.31
47.98
Manager TitleAgeSince
Chief Executive Officer 69 2014-05-31
Director of Finance/CFO 51 2024-04-30
Chief Tech/Sci/R&D Officer 44 2024-12-31
Director TitleAgeSince
Director/Board Member 69 2014-05-31
Director/Board Member 69 2014-05-31
Director/Board Member 44 2025-02-28
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%-10.05% - - 406M
+1.23%+1.87%-0.15%+28.45% 45.91B
+0.65%+4.90%+44.58%+28.93% 44.25B
+0.31%-3.17%+349.46%+536.63% 41.99B
+1.36%+3.19%+6.17%+68.83% 39.58B
+1.75%-1.53%+12.22%+41.11% 31.08B
+0.66%+6.43%+24.67%+127.26% 17.21B
-3.55%-8.08% - - 16.27B
+2.92%+8.40%+22.46%+39.73% 14.96B
-0.86%+3.87%-1.77%-34.56% 13.42B
Average +0.45%+0.37%+57.21%+104.55% 26.51B
Weighted average by Cap. +0.74%+0.67%+72.47%+126.58%

Financials

2026 *2027 *
Net sales 265M 310M 39.48M 34.39M 32.55M 29.57M 55.24M 3.78B 55.51M 388M 150M 1.92B 148M 145M 6.15B 630M 737M 93.88M 81.77M 77.39M 70.31M 131M 8.99B 132M 922M 356M 4.57B 353M 345M 14.63B
Net income - -
Net Debt -816M -955M -122M -106M -100M -91.18M -170M -11.66B -171M -1.2B -462M -5.93B -457M -447M -18.97B -1.01B -1.18B -150M -131M -124M -112M -210M -14.36B -211M -1.47B -569M -7.3B -563M -551M -23.37B
Logo IMPACT Therapeutics, Inc
IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.
Employees
-
Date Price Change Volume
26-09-17 HK$11.28 +0.09% 3,453,400
26-09-16 HK$11.27 -3.84% 3,221,400
26-09-15 HK$11.72 -1.92% 6,442,400
26-09-14 HK$11.95 -7.36% 14,993,000
26-09-11 HK$12.90 +11.02% 9,540,600
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
9.642CNY
Average target price
27.28CNY
Spread / Average Target
+182.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7630 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!